We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Molecular Blood Test Developed for Kidney Cancer

By LabMedica International staff writers
Posted on 29 Aug 2017
Kidney cancer is usually caught because of the symptoms a patient develops, but it is also possible for kidney cancer to be asymptomatic, with tumors growing quite large before causing pain or other noticeable problems.

The mechanisms involved in renal cell carcinoma (RCC) development and progression remain unclear, and new biomarkers are needed in routine practice to improve the diagnostic and/or prognostic accuracy. More...
A blood test for kidney cancer, which is under development, could improve screening for this disease and help ensure that asymptomatic patients are diagnosed while their cancer is still treatable.

A team of scientists at the Jinling Hospital (Nanjing, China) measured the concentrations of 754 different microRNAs (miRNA) in blood samples from 33 patients with the most common type of kidney cancer (renal cell carcinoma) and 33 healthy individuals. An initial microarray survey of 754 miRNAs was firstly performed using the TaqMan Low Density Array followed by a hydrolysis probe-based quantitative reverse transcription polymerase chain reaction (RT-qPCR) validation from serum samples to identify significantly dysregulated miRNAs in RCC. The expression levels of miR-651 and miR-708 in 17 paired tumor tissues were also examined. Furthermore, in vitro tests including CCK8 proliferation, transwell and wound healing assays were conducted to explore the potential functions of miR-651 and miR-708 in RCC. Luciferase reporter assays combined with Western blotting were employed to validate the target genes.

The team found that the serum levels of four miRNAs were verified to be significantly increased, whereas the levels of four miRNAs were markedly decreased in RCC patients compared with the non-cancer controls. Of these eight microRNAs, statistical analysis revealed that the two known as miR-651 and miR-708, which decreased in the kidney cancer patients, exhibited the largest areas under the curve (0.888 and 0.832, respectively). This means that a test for these microRNAs could diagnose renal cell carcinoma with relatively high accuracy. They also investigated the functions of miR-651 and miR-708 and found evidence suggesting they act as tumor suppressors. A therapeutic that increases levels of miR-651 and miR-708 could therefore potentially serve as a new treatment for renal cell carcinoma.

Chunni Zhang, PhD, the lead author of the study, said, “The mechanisms involved in renal cell carcinoma development and progression are unclear, and there is no standard serological biomarker to facilitate diagnosis in patients with this disease. Both miR-651 and miR-708 may potentially serve as novel biomarkers for renal cell carcinoma and may act as tumor suppressors. Our findings indicate that targeting miR-651 and miR-708 by a genetic approach may provide a novel strategy for the treatment of renal cell carcinoma.” The study was presented at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, held July 30 to August 3, in San Diego, CA, USA.

Related Links:
Jinling Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.